Xilio Therapeutics: Funding, Investors & Team (Sep 2026)
Xilio Therapeutics is a biotech company that provides cancer immunotherapies aimed at enhancing patient results by activating the immune system directly at the tumor site. Utilizing their unique technology, they create tumor-specific immunotherapies that enhance the effectiveness of established immuno-oncology treatments while limiting side effects in other parts of the body.
Xilio Therapeutics has raised $111M across 4 funding rounds on record, the most recent an undisclosed round of $40.0M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Xilio Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Xilio Therapeutics Funding Rounds
Xilio Therapeutics raised $11.3M in an undisclosed round announced in Mar 2024.
11 months later, an undisclosed round of $10.0M was announced in Feb 2025.
4 months later, an undisclosed round of $50.0M was announced in Jun 2025.
8 months later, an undisclosed round of $40.0M was announced in Feb 2026.
Xilio Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Xilio Therapeutics Funding Compared to Other Biotechnology Startups
Xilio Therapeutics' latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Xilio Therapeutics in Biotechnology and Waltham
Companies Similar to Xilio Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Xilio Therapeutics Funding FAQs
What does Xilio Therapeutics do?
Xilio Therapeutics is a biotech company that provides cancer immunotherapies aimed at enhancing patient results by activating the immune system directly at the tumor site. Utilizing their unique technology, they create tumor-specific immunotherapies that enhance the effectiveness of established immuno-oncology treatments while limiting side effects in other parts of the body.
How much funding has Xilio Therapeutics raised?
Xilio Therapeutics has raised $111M across 4 rounds on record. The most recent is an undisclosed round of $40.0M announced in Feb 2026.
When did Xilio Therapeutics last raise funding?
Xilio Therapeutics' most recent funding round on record is an undisclosed round of $40.0M, announced in Feb 2026.
Who founded Xilio Therapeutics?
FundedIQ lists Uli Rodeck (Founder) at Xilio Therapeutics.
Where is Xilio Therapeutics headquartered?
Xilio Therapeutics is based in Waltham, Massachusetts, United States.
How many employees does Xilio Therapeutics have?
Xilio Therapeutics is in the 51-100 employee band.
How does Xilio Therapeutics' funding compare to other Biotechnology startups?
Xilio Therapeutics' latest round of $40.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Xilio Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Xilio Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.